MA27551A1 - Composition immunogene - Google Patents

Composition immunogene

Info

Publication number
MA27551A1
MA27551A1 MA28275A MA28275A MA27551A1 MA 27551 A1 MA27551 A1 MA 27551A1 MA 28275 A MA28275 A MA 28275A MA 28275 A MA28275 A MA 28275A MA 27551 A1 MA27551 A1 MA 27551A1
Authority
MA
Morocco
Prior art keywords
ipv
formulation
immunogenic composition
antigenicity
immunogenicity
Prior art date
Application number
MA28275A
Other languages
English (en)
Inventor
Mayeresse Yves
Stephenne Jean
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32234471&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27551(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0225532A external-priority patent/GB0225532D0/en
Priority claimed from GBGB0225520.6A external-priority patent/GB0225520D0/en
Priority claimed from GB0225543A external-priority patent/GB0225543D0/en
Priority claimed from GB0317371A external-priority patent/GB0317371D0/en
Priority claimed from GB0317381A external-priority patent/GB0317381D0/en
Priority claimed from GB0317380A external-priority patent/GB0317380D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA27551A1 publication Critical patent/MA27551A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions immunogènes comprenant une formulation solide séchée ou une formulation liquide hautement visqueuse d'un poliovirus inactivé (IPV) et un agent stabilisant, l'IPV retenant son antigénicité et/ou son immunogénicité, ainsi que des procédés de fabrication de la formulation séchée d'IPV qui retient son antigenicité/immunogénicité.
MA28275A 2002-11-01 2005-05-11 Composition immunogene MA27551A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0225532A GB0225532D0 (en) 2002-11-01 2002-11-01 Drying process
GBGB0225520.6A GB0225520D0 (en) 2002-11-01 2002-11-01 Drying process
GB0225543A GB0225543D0 (en) 2002-11-01 2002-11-01 Immunogenic composition
GB0317371A GB0317371D0 (en) 2003-07-24 2003-07-24 Immunogenic composition
GB0317381A GB0317381D0 (en) 2003-07-24 2003-07-24 Drying method
GB0317380A GB0317380D0 (en) 2003-07-24 2003-07-24 Drying method

Publications (1)

Publication Number Publication Date
MA27551A1 true MA27551A1 (fr) 2005-10-03

Family

ID=32234471

Family Applications (2)

Application Number Title Priority Date Filing Date
MA28276A MA27644A1 (fr) 2002-11-01 2005-05-11 Sechage
MA28275A MA27551A1 (fr) 2002-11-01 2005-05-11 Composition immunogene

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA28276A MA27644A1 (fr) 2002-11-01 2005-05-11 Sechage

Country Status (27)

Country Link
US (3) US7927858B2 (fr)
EP (3) EP2395073B1 (fr)
JP (2) JP4579156B2 (fr)
KR (2) KR101058978B1 (fr)
AR (2) AR041880A1 (fr)
AT (1) ATE352316T1 (fr)
AU (2) AU2003287980B2 (fr)
BR (1) BR0315767A (fr)
CA (2) CA2503871C (fr)
CY (2) CY1119362T1 (fr)
DE (1) DE60311526T2 (fr)
DK (2) DK1556477T3 (fr)
ES (3) ES2649048T3 (fr)
HU (1) HUE034801T2 (fr)
IL (2) IL168054A (fr)
IS (2) IS7806A (fr)
LT (2) LT1556477T (fr)
MA (2) MA27644A1 (fr)
MX (3) MXPA05004528A (fr)
MY (2) MY132859A (fr)
NO (3) NO342741B1 (fr)
NZ (2) NZ539613A (fr)
PL (2) PL213647B1 (fr)
PT (2) PT1556477T (fr)
SI (2) SI1556477T1 (fr)
TW (2) TWI332843B (fr)
WO (2) WO2004039417A2 (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2395073B1 (fr) * 2002-11-01 2017-09-06 GlaxoSmithKline Biologicals S.A. Séchage
US20080176209A1 (en) * 2004-04-08 2008-07-24 Biomatrica, Inc. Integration of sample storage and sample management for life science
CA2560513A1 (fr) * 2004-04-08 2005-12-01 Biomatrica, Inc. Integration du stockage et de la gestion d'echantillons pour les sciences de la vie
US20060099567A1 (en) * 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
GB0409795D0 (en) * 2004-04-30 2004-06-09 Glaxosmithkline Biolog Sa Drying method
TWI398272B (zh) * 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US8398983B2 (en) 2005-06-27 2013-03-19 Glaxosmithkline Biologicals, S.A. Immunogenic composition
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
US8097245B2 (en) * 2005-12-28 2012-01-17 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
US8945582B2 (en) * 2006-09-07 2015-02-03 Glaxosmithkline Biologicals S.A. Vaccine
US8460726B2 (en) * 2006-12-18 2013-06-11 Advanced Bionutrition Corporation Dry food product containing live probiotic
BRPI0810778A2 (pt) 2007-05-02 2011-09-13 Glaxosmithkline Biolog Sa kit, vacina combinada, e, métodos de diminuição da interferência de vizinhança de crm sobre um antìgeno sensìvel em um esquema de imunização primária de uma vacina, e de diminuição da interferência de vizinhança sobre um antìgeno sensìvel, e, uso de conjugados de sacarìdeo
EP2148923B1 (fr) * 2007-05-18 2012-08-22 MedImmune, LLC Conservation de substances biologiquement actives par mousse lyophilisée
KR20100049019A (ko) * 2007-06-16 2010-05-11 이니그마 다이아그노스틱스 리미티드 조성물
GB0711683D0 (en) * 2007-06-16 2007-07-25 Enigma Diagnostics Ltd Compositions
MX2010001054A (es) * 2007-07-26 2010-04-21 Sanofi Pasteur Ltd Composiciones adyuvantes antigenicas y metodos.
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
WO2010111565A2 (fr) 2009-03-27 2010-09-30 Advanced Bionutrition Corporation Vaccins microparticulaires utilisables pour procéder à une vaccination et à des rappels par voie orale ou nasale chez les animaux, dont les poissons
WO2010138522A2 (fr) 2009-05-26 2010-12-02 Advanced Bionutrition Corporation Composition de poudre sèche stable comprenant des micro-organismes biologiquement actifs et/ou des matériaux bioactifs et procédés de fabrication
EP2475393A4 (fr) * 2009-09-14 2013-08-21 Vu Truong-Le Formulation pour la stabilisation à température ambiante d'un vaccin bactérien atténué vivant
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
US8834951B2 (en) 2010-01-28 2014-09-16 Advanced Bionutrition Corporation Dry glassy composition comprising a bioactive material
FR2960781B1 (fr) * 2010-06-07 2013-11-22 Sanofi Pasteur Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue
US9845489B2 (en) 2010-07-26 2017-12-19 Biomatrica, Inc. Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
CA2806670A1 (fr) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions de stabilisation d'adn, d'arn, de proteines dans le sang et d'autres echantillons biologiques lors du transport et du stockage a temperatures ambiantes
WO2012021783A2 (fr) 2010-08-13 2012-02-16 Advanced Bionutrition Corporation Composition de stabilisation pour le stockage à sec de matériels biologiques
BR112013005049A2 (pt) 2010-09-02 2016-05-31 Sanofi Pasteur estabilizador para a preparação de uma composição vacina da pólio seca injetável
AU2011336413B2 (en) 2010-12-02 2015-01-22 Oncolytics Biotech Inc. Liquid viral formulations
MX349294B (es) 2010-12-02 2017-07-21 Oncolytics Biotech Inc Formulaciones virales liofilizadas.
US8512679B2 (en) 2011-03-04 2013-08-20 Elwha Llc Glassy compositions
CA2832560A1 (fr) * 2011-04-07 2012-10-18 Glaxosmithkline Llc Formulations a viscosite reduite
US20140023655A1 (en) * 2011-04-07 2014-01-23 Glaxosmithkline Llc Formulations with reduced viscosity
CN102793919A (zh) 2011-05-20 2012-11-28 日东电工株式会社 医药组合物及医药组合物的制造方法
SG10201604104PA (en) 2011-10-25 2016-07-28 Prothena Therapeutics Ltd Antibody formulations and methods
US9725703B2 (en) 2012-12-20 2017-08-08 Biomatrica, Inc. Formulations and methods for stabilizing PCR reagents
TW201601776A (zh) * 2013-10-03 2016-01-16 Nitto Denko Corp 流感疫苗乾燥製劑、及流感疫苗乾燥製劑之製造方法
US20160317646A1 (en) * 2013-12-19 2016-11-03 Crucell Holland B.V. Formulations for virosomes
AU2015217149B2 (en) 2014-02-11 2020-09-10 Massachusetts Institute Of Technology Novel full spectrum anti-dengue antibody
CN106572650B (zh) 2014-06-10 2021-08-31 生物马特里卡公司 在环境温度下稳定凝血细胞
AR101256A1 (es) * 2014-07-21 2016-12-07 Sanofi Pasteur Composición vacunal que comprende ipv y ciclodextrinas
MX380541B (es) 2015-06-30 2025-03-12 Soc Des Produits Nestle S A Star Composición adecuada para proteger microorganismos.
US12558395B2 (en) 2015-07-29 2026-02-24 Advanced Bionutrition Corp. Stable dry probiotic compositions for special dietary uses
JP6889699B2 (ja) 2015-07-29 2021-06-18 アドバンスド バイオニュートリション コープ． 特定栄養用途のための安定乾燥プロバイオティクス組成物
WO2017041083A1 (fr) * 2015-09-04 2017-03-09 Inventprise, Llc Compositions de vaccin stabilisés de vlp
SG11201804776SA (en) 2015-12-08 2018-07-30 Biomatrica Inc Reduction of erythrocyte sedimentation rate
KR102906912B1 (ko) 2016-09-02 2026-01-05 사노피 파스퇴르 인크 네이세리아 메닌기티디스 백신
EP3781192A1 (fr) * 2018-04-16 2021-02-24 Merck Patent GmbH Additifs pour formulations protéiques en vue d'améliorer la stabilité thermique
KR20210045443A (ko) * 2018-09-28 2021-04-26 가부시기가이샤오오쓰까세이야꾸고오죠오 아카보즈 또는 스타키오스를 포함하는 포유동물 세포 보존용 액
JP7513614B2 (ja) 2018-12-20 2024-07-09 インターベット インターナショナル ベー． フェー． プライム－ブーストワクチン接種レジメン

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US509893A (en) * 1893-12-05 William griesser
DE1157734B (de) 1961-08-16 1963-11-21 Behringwerke Ag Verfahren zur Herstellung von haltbaren, oral zu verabreichenden Poliomyelitisvirus-Praeparaten
US3767790A (en) * 1972-02-11 1973-10-23 Nat Patent Dev Corp Microorganisms
US3929132A (en) * 1973-04-10 1975-12-30 Alza Corp Osmotic dispenser
DE3071552D1 (en) 1979-09-21 1986-05-22 Hitachi Ltd Semiconductor switch
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
GB8323094D0 (en) * 1983-08-26 1983-09-28 Franks F Preservation of cells
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
ATE68524T1 (de) 1985-07-09 1991-11-15 Quadrant Bioresources Ltd Beschuetzung von proteinen und aehnlichem.
GB8604983D0 (en) * 1986-02-28 1986-04-09 Biocompatibles Ltd Protein preservation
GB8715238D0 (en) 1987-06-29 1987-08-05 Quadrant Bioresources Ltd Food process
GB8801338D0 (en) * 1988-01-21 1988-02-17 Quadrant Bioresources Ltd Preservation of viruses
DE3819530A1 (de) * 1988-06-08 1989-12-21 Westphal Geb Jauch Christel Dr Verfahren, traeger und testsatz fuer die kultivierung und mikroskopische untersuchung von zellen
RU2121481C1 (ru) 1988-12-16 1998-11-10 Де Стат Дер Недерланден Вертегенвордигд Дор де Министр Ван Велзейн, Волксгезондхейд эн Кюлтюр Модифицированный пневмолизин, рекомбинантная плазмида, способ получения модифицированного пневмолизина, вакцина
ZA907737B (en) * 1989-09-29 1991-07-31 Nisshin Oil Mills Ltd Stable immunogen composition for oral administration
JPH03161441A (ja) 1989-11-20 1991-07-11 Senjiyu Seiyaku Kk メイラード反応阻害剤
EP1338607A3 (fr) 1990-07-16 2004-08-18 University Of North Carolina At Chapel Hill Protéines antigéniques à action limitée par l'incorporation de fer tirées de la bactérie N. Meningitis et associées à la famille de toxines des hémolysines.
CA2087958C (fr) 1990-08-23 2007-05-15 P. Frederick Sparling Proteines fixatrices de la transferrine de neisseria gonorrhoeae et de neisseria meningitidis
US5912336A (en) 1990-08-23 1999-06-15 University Of North Carolina At Chapel Hill Isolated nucleic acid molecules encoding transferrin binding proteins from Neisseria gonorrhoeae and Neisseria meningitidis
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
FR2682041B1 (fr) 1991-10-03 1994-01-14 Pasteur Merieux Serums Vaccins Vaccin contre les infections a neisseria meningitidis.
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
AU685047B2 (en) 1992-02-11 1998-01-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
DE69333110T2 (de) 1992-03-02 2004-05-06 Chiron S.P.A. Mit dem cytotoxin von helicobacter pylori assoziiertes, immunodominantes antigen verwendbar in impfstoffen und zur diagnose
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
FI945483A7 (fi) 1992-05-23 1995-01-20 Smithkline Beecham Biologicals S A Hepatiitti B - pinta-antigeenejä ja muita antigeenejä sisältäviä yhdistelmärokotteita
FR2692592B1 (fr) 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
DK0594950T3 (da) 1992-10-27 1999-09-13 American Cyanamid Co Pædiatrisk kombinationsvaccine med forbedret immunogenicitet af hver vaccinekomponent
ES2185658T3 (es) 1993-05-18 2003-05-01 Univ Ohio State Res Found Vacuna para la otitis media.
AU3191495A (en) 1994-08-09 1996-03-07 Nisshin Oil Mills, Ltd., The Peroral immunogen composition and process for producing the same
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6265567B1 (en) 1995-04-07 2001-07-24 University Of North Carolina At Chapel Hill Isolated FrpB nucleic acid molecule
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
DE69628007T2 (de) * 1995-06-07 2003-11-27 Elan Drug Delivery Ltd., Ruddington Verfahren zur stabilen einarbeitung von substanzen in trockene geschäumte glasmatrizen und auf diese weise hergestellte zusammensetzungen
CZ394297A3 (cs) 1995-06-07 1998-04-15 Biochem Vaccines Inc. Streptokokové proteiny teplotního šoku ze skupiny HSP70
TR199701547T1 (xx) 1995-06-07 1998-03-21 Smithkline Beecham Biologicals S.A. Polisakarit antijen protein e�leni�i i�eren a��.
PL184872B1 (pl) 1995-06-23 2003-01-31 Smithkline Beecham Biolog Kombinowana szczepionkaĆ zestaw do przygotowania kombinowanej szczepionkiĆ sposób wytwarzania kombinowanej szczepionki i jej zastosowanie
DE19543770C2 (de) * 1995-11-24 1998-11-05 Metallgesellschaft Ag Vorrichtung zur Messung von kondensierter Feuchtigkeit in Vorrichtungen und/oder Rohrleitungen der chemischen Technik und deren Verwendung
WO1997029773A1 (fr) 1996-02-13 1997-08-21 The Nisshin Oil Mills, Ltd. Emulsion et poudre renfermant un vaccin et destinees a une administration orale, et procede de production associe
DE69735715T2 (de) 1996-05-01 2007-03-29 The Rockefeller University Cholin-bindendes Protein, welches als gegen Pneumokokken gerichtetes Vakzin verwendet wird
CA2256333A1 (fr) * 1996-05-29 1997-12-04 Victor Bronshtein Accroissement de la duree de conservation par vitrification
US5766520A (en) * 1996-07-15 1998-06-16 Universal Preservation Technologies, Inc. Preservation by foam formation
BRPI9710460B8 (pt) * 1996-07-02 2021-05-25 Aventis Pasteur composição imunogênica multi-valente e composição de vacina
FR2751000B1 (fr) 1996-07-12 1998-10-30 Inst Nat Sante Rech Med Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques
DE19630390A1 (de) 1996-07-26 1998-01-29 Chiron Behring Gmbh & Co Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
JP4469026B2 (ja) 1996-10-31 2010-05-26 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅの抗原およびワクチン
US6051238A (en) * 1996-12-20 2000-04-18 Merck & Co., Inc. Stabilizers for lyophilized mumps vaccines
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
SE511963C2 (sv) 1997-04-23 1999-12-20 Ericsson Telefon Ab L M Anordning och förfarande för bestämning av linjespänning i en abonnentlinjekrets
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
JP2001510031A (ja) 1997-07-21 2001-07-31 ノース・アメリカン・ヴァクシン・インコーポレーテッド ワクチンとしての修飾された免疫原ニューモリシン組成物
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
CA2303105A1 (fr) * 1997-09-15 1999-03-25 Pasteur Merieux Msd Vaccins multivalents
KR20010032336A (ko) 1997-11-21 2001-04-16 브랑디 빠스깔 클라미디아 뉴모니아 게놈 서열과 폴리펩티드, 이의 단편및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
AU5459698A (en) * 1997-11-26 1999-06-15 Universal Preservation Technologies, Inc. Preservation of sensitive biological samples by vitrification
KR100735651B1 (ko) 1997-11-28 2007-07-06 세로노 제네틱스 인스티튜트 에스.에이. 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
AU1979599A (en) 1998-01-14 1999-08-02 Chiron S.P.A. (neisseria meningitidis) antigens
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
DE69942176D1 (de) 1998-04-07 2010-05-06 Medimmune Llc Choline-bindende proteine derivate aus pneumokoken als impfstoff
GB9807721D0 (en) 1998-04-08 1998-06-10 Chiron Spa Antigen
EP2261352A3 (fr) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
US6306345B1 (en) 1998-05-06 2001-10-23 Universal Preservation Technologies, Inc. Industrial scale barrier technology for preservation of sensitive biological materials at ambient temperatures
BR9914374A (pt) 1998-10-09 2002-09-17 Chiron Corp Sequências genÈmicas de neisseria e métodos para seu uso
WO2000023595A1 (fr) 1998-10-22 2000-04-27 The University Of Montana Proteines omp85 de neisseria gonorrhoeae et de neisseria meningitidis, compositions renfermant lesdites proteines et methodes d'utilisation correspondantes
JP2002529069A (ja) 1998-11-12 2002-09-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クラミジア・ニューモニエのゲノム配列
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
ES2275499T3 (es) 1999-03-19 2007-06-16 Glaxosmithkline Biologicals S.A. Vacuna contra streptococcus pneumoniae.
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
WO2000061761A2 (fr) 1999-04-09 2000-10-19 Techlab, Inc. Support proteique recombinant de la toxine a pour vaccins conjugues polysaccharides
PT1233784E (pt) 1999-12-02 2008-11-03 Novartis Vaccines & Diagnostic Composições e métodos para a estabilização de moléculas biológicas após a liofilização
PT2289545T (pt) 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
ES2281409T3 (es) 2000-02-28 2007-10-01 Novartis Vaccines And Diagnostics S.R.L. Expresion heterologa de proteinas de neisseria.
HU227893B1 (en) * 2000-06-29 2012-05-29 Glaxosmithkline Biolog Sa Vaccine compositions
WO2002002606A2 (fr) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation contre une infection par chlamydia pneumoniae
KR100385711B1 (ko) 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
DK1328543T3 (da) 2000-10-27 2009-11-23 Novartis Vaccines & Diagnostic Nukleinsyrer og proteiner fra streptococcus-gruppe A & B
CA2452720C (fr) 2001-07-26 2012-04-17 Chiron S.R.L. Vaccins comprenant des adjuvants aluminium et histidine
US7135180B2 (en) * 2002-04-11 2006-11-14 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
EP2395073B1 (fr) * 2002-11-01 2017-09-06 GlaxoSmithKline Biologicals S.A. Séchage
GB0409795D0 (en) * 2004-04-30 2004-06-09 Glaxosmithkline Biolog Sa Drying method
US9473463B2 (en) 2014-07-29 2016-10-18 Combined Conditional Access Development & Support, LLC Control word and associated entitlement control message caching and reuse

Also Published As

Publication number Publication date
CA2503871C (fr) 2012-12-11
PT2395073T (pt) 2017-11-24
EP2395073A2 (fr) 2011-12-14
PT1556477T (pt) 2017-11-14
PL215237B1 (pl) 2013-11-29
MXPA05004528A (es) 2005-07-26
KR20050075766A (ko) 2005-07-21
WO2004039399A1 (fr) 2004-05-13
MX343419B (es) 2016-11-04
AU2003287980B2 (en) 2009-06-25
EP1556477A2 (fr) 2005-07-27
NZ539613A (en) 2008-09-26
CA2503871A1 (fr) 2004-05-13
KR101058978B1 (ko) 2011-08-23
IS7806A (is) 2005-04-18
DK1556477T3 (en) 2017-10-23
MXPA05004675A (es) 2005-06-08
PL376950A1 (pl) 2006-01-09
US20060127414A1 (en) 2006-06-15
JP2006512406A (ja) 2006-04-13
MA27644A1 (fr) 2005-12-01
JP4579156B2 (ja) 2010-11-10
KR20050084626A (ko) 2005-08-26
DK2395073T3 (en) 2017-10-23
LT1556477T (lt) 2017-10-25
NO20051998D0 (no) 2005-04-25
US20060127415A1 (en) 2006-06-15
US8409587B2 (en) 2013-04-02
MY145693A (en) 2012-03-30
TWI332843B (en) 2010-11-11
KR101130948B1 (ko) 2012-03-30
IL168052A0 (en) 2011-08-01
BR0315767A (pt) 2005-09-06
EP1556477B1 (fr) 2017-08-09
NO20052010D0 (no) 2005-04-25
NO342741B1 (no) 2018-08-06
SI1556477T1 (sl) 2017-12-29
PL377170A1 (pl) 2006-01-23
SI2395073T1 (sl) 2017-12-29
IS3028B (is) 2021-05-15
HK1085380A1 (en) 2006-08-25
WO2004039417A2 (fr) 2004-05-13
LT2395073T (lt) 2017-11-10
AU2003287980A1 (en) 2004-05-25
US7927858B2 (en) 2011-04-19
NO344759B1 (no) 2020-04-14
CY1119504T1 (el) 2018-03-07
DE60311526T2 (de) 2007-10-31
AU2003278166A1 (en) 2004-05-25
EP1575612A1 (fr) 2005-09-21
NO20052010L (no) 2005-06-24
PL213647B1 (pl) 2013-04-30
NZ539706A (en) 2008-03-28
HUE034801T2 (en) 2018-02-28
IL168052A (en) 2015-03-31
EP2395073B1 (fr) 2017-09-06
JP2006504801A (ja) 2006-02-09
AR041880A1 (es) 2005-06-01
NO20051998L (no) 2005-06-24
NO20180874A1 (no) 2005-06-24
AR041881A1 (es) 2005-06-01
ES2280809T3 (es) 2007-09-16
CY1119362T1 (el) 2018-03-07
ATE352316T1 (de) 2007-02-15
TW200501981A (en) 2005-01-16
US20110159038A1 (en) 2011-06-30
DE60311526D1 (de) 2007-03-15
ES2649048T3 (es) 2018-01-09
IL168054A (en) 2011-06-30
ES2645924T3 (es) 2017-12-11
IS7805A (is) 2005-04-18
CA2503946C (fr) 2016-08-16
AU2003278166B2 (en) 2009-01-29
WO2004039417A3 (fr) 2004-12-16
CA2503946A1 (fr) 2004-05-13
US8449865B2 (en) 2013-05-28
MY132859A (en) 2007-10-31
TW200501980A (en) 2005-01-16
EP1575612B1 (fr) 2007-01-24
EP2395073A3 (fr) 2012-01-25

Similar Documents

Publication Publication Date Title
MA27551A1 (fr) Composition immunogene
IL143673A0 (en) Compositions comprising 1,1,1,3,3-pentaflurobutane and use of said compositions
PT1073470E (pt) Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos
ATE290059T1 (de) Tensidzusammensetzung enthaltend geminitenside und co-amphiphile, ihre herstellung und ihre verwendung
BR0108058A (pt) Corpo maciço
ATE263157T1 (de) Nematizide trifluorbutene
MXPA04001224A (es) Agentes para incrementar la respuesta inmune.
WO2003000200A3 (fr) ss-2'-OU 3'-HALONUCLEOSIDES
HUP9901053A2 (hu) Fertőtlenítő készítmények és felületek fertőtlenítésére szolgáló eljárások
WO2004069152A3 (fr) ?4,5 glycuronidase et ses utilisations
BR0000654A (pt) Preparação de composição de borracha vulcanizada com peróxido e artigos tendo ela pelo menos como um dos seus componentes
AU6362100A (en) Derivatized polyurethane compositions and methods of making
BR0109846A (pt) Uso de uma composição que compreende um anticorpo ou um fragmento de ligação de antìgeno deste, e conjunto
BRPI0403461A (pt) composições estabilizadas contendo um agente ativo lábil ao oxigênio
MXPA03008801A (es) Aril oxima-piperazinas utiles como antagonistas de ccr5.
DK1546067T3 (da) Rygesammensætning
HUP0402183A2 (hu) Folyékony élesztőkészítmények
ATE545434T1 (de) Stabilisierte zusammensetzungen
WO2002098924A3 (fr) Compositions contenant des peroxydes fluores, leurs procedes d'elaboration et leur utilisation
DK1163248T3 (da) 1,5-anhydro-D-fructose substitueret med en hydrofob gruppe til brug som en antioxidant og/eller emulgator
ATE359350T1 (de) Verdickte wässrige zusammensetzungen
ATE364619T1 (de) Tibolonformulierungen
BR0311974A (pt) Composições de peróxido (estabilizadas) fleumatizadas com um agente fleumatizante insaturado especìfico
BRPI0411435A (pt) método para controlar mau cheiro, e, composição desodorizante
AU2001287673A1 (en) Novel trioxepan compounds